Sebetralstat - KalVista Pharmaceuticals
Alternative Names: EKTERLY; KVD-900Latest Information Update: 08 Jul 2025
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Amines; Aza compounds; Esters; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
Most Recent Events
- 08 Jul 2025 Phase-III clinical trials in Hereditary angioedema (PO, Fast dissolve), before July 2025 (KalVista Pharmaceuticals pipeline, July 2025)
- 07 Jul 2025 Launched for Hereditary angioedema (In the elderly, In adolescents, In adults) in USA (PO) - First global launch
- 07 Jul 2025 Efficacy data from the phase III KONFIDENT-S trial in Hereditary angioedema released by KalVista Pharmaceuticals